XSOLLA
8.8.2024 18:01:37 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the opening of its first Canadian office in Montreal in collaboration with GameAddik. This strategic expansion into one of North America's most dynamic tech hubs underscores Xsolla's dedication to innovation and its mission to better serve the burgeoning gaming industry and developers in Quebec and across Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808870268/en/
(Graphic: Xsolla)
Montreal has long been recognized for its dynamic gaming ecosystem and innovative tech community. By establishing a presence in this thriving city, Xsolla aims to expand its operations with incredible local talent and foster closer relationships with regional developers. The new office will serve as a hub for Xsolla's operations in Canada, enhancing its ability to offer tailored and localized solutions to its current partners and thousands of new game developers and publishers in the region.
"Montreal is renowned for its dynamic gaming ecosystem and innovative tech community. Our presence here will enable us to better support our local and global partners and tap into the incredible local talent pool," said Xsolla's president, David Stelzer. “This new office in Montreal will be crucial in strengthening our relationships with local game developers and facilitating our mission to empower our partners to reach their full potential.”
As part of this expansion, Xsolla plans to hire up to 50 regional employees over the next two years, targeting a mix of roles in business development, customer support, and technical services. This investment will strengthen its capacity to deliver cutting-edge solutions and exceptional service.
This strategic partnership with GameAddik originated from the successful cross-service opportunities explored with its dedicated marketing solution, GameRebellion, creating a robust support system for game developers in Canada.
"We are excited about our collaboration with Xsolla, as our GameRebellion project shares a common vision of empowering studios to achieve greater success," said Alain Carpentier, CTO at GameAddik.
"Our partnership with Xsolla is a game-changer for GameAddik," said Eric Jodoin, CEO of GameAddik. "Teaming up with such a prominent company allows us to better support the industry in striving for success."
The new office will be a one-stop shop for companies looking for industry-leading and cutting-edge solutions to fund, launch, market, monetize, and sell their games to local gamers and fans of their games worldwide. Xsolla provides advanced tools and services to help game developers accelerate their business by reaching players who want to pay for their gaming experiences locally using their preferred payment methods. With the ability to enable transactions in over 130 currencies and 20 languages, Xsolla has already facilitated access to new gamers for game developers worldwide.
For more information about the Xsolla Canadian office, please visit xsolla.pro/montreal.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com.
About GameAddik
Founded in 2015, GameAddik is an advertising technology company that provides tech-driven marketing solutions for the gaming industry. Trusted by over 200 global brands, GameAddik is a leader in understanding gaming audiences and delivering measurable performance marketing solutions for its clients across its three business segments: PWN Games (performance marketing), Elusive (performance-driven influencer marketing), and GameRebellion (game audience and industry data and analytics).
For more information, please visit gameaddik.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808870268/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom